Who can administer
May be administered by registered competent doctor or nurse/midwife
Important information
- There are two intravenous ibandronic acid preparations available - Bonviva and Bondronat
- Bonviva is licensed for the treatment of osteoporosis
- Bondronat is licensed for the treatment of Tumour Induced Hypercalcaemia, and for the prevention of skeletal related events in patients with breast cancer or bone metastases
- Only Bonviva is available in GUH, and this preparation should only be used for osteoporosis
- See under 'Dose' for adjustments required in renal impairment
- Ensure pre-counselling and baseline assessment for risk of adverse reactions such as osteonecrosis of the jaw and external auditory canal
Available preparations
Bonviva 3mg per 3mL pre-filled syringe
Bondronat 2mg per 2mL vial - not stocked in GUH
Bondronat 6mg per 6mL vial - not stocked in GUH
Reconstitution
Already in solution
Infusion fluids
Not required - product ready for use (Bonviva)
Methods of intravenous administration
Bolus intravenous injection (Bonviva only)
- Administer over 15 to 30 seconds
Dose in adults
Treatment of osteoporosis in postmenopausal women at increased risk of fracture
- Give 3mg by bolus intravenous injection every three months
Renal impairment
- Not recommended for patients with Creatinine clearance less than 30mL/minute
Further information
- All patients must receive continuous supplemental calcium and Vitamin D
- Influenza like symptoms have been reported, typically in association with the first dose
- Existing hypocalcaemia must be corrected before starting Bonviva
Storage
Store below 250C
References
SPC 29/03/2021
Therapeutic classification
Bisphosphonate
